Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMND05
- Development stage
- Preclinical
- Lead developer
- Biomind Labs
- Modality
- Small Molecules
01
Overview
BMND05 is a preclinical drug candidate being developed by Biomind Labs for the treatment of chronic pain. It is a psychedelic-based pharmaceutical product, potentially utilizing 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) as its active ingredient. The drug is characterized as having anti-inflammatory properties and is part of Biomind Labs' broader effort to develop novel delivery systems, including nanotechnology, for psychiatric and neurological conditions. BMND05 is currently in the evaluation or preclinical stage of development, aiming to provide a new therapeutic approach for chronic pain management through the modulation of serotonin receptors and inflammatory pathways.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on BMND05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMND05.